Mirikizumab-Mrkz
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Guselkumab (Tremfya) - an IL-23 antagonist for Crohn's disease.
Journal: The Medical letter on drugs and therapeutics
Published: June 03, 2025
Mirikizumab (Omvoh) - an IL-23 antagonist for Crohn's disease.
Journal: The Medical letter on drugs and therapeutics
Published: May 05, 2025
Guselkumab (Tremfya) for ulcerative colitis.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2025
Risankizumab (Skyrizi) for ulcerative colitis.
Journal: The Medical letter on drugs and therapeutics
Published: November 07, 2024
Mirikizumab (Omvoh) for ulcerative colitis.
Journal: The Medical letter on drugs and therapeutics
Published: March 11, 2024
Mirikizumab-mrkz.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: December 28, 2023
Mirikizumab (Omvoh™) for ulcerative colitis.
Journal: Trends in pharmacological sciences
Published: November 30, 2023
Showing 1-9 of 9
Last Updated: 04/28/2026